trial

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

NCTId NCT02720263
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 48 (actual)
Sponsored by Astellas Pharma Global Development, Inc.
Primary completion 2017-06-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
48 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2016-03-28
Primary completion
2017-06-08
Eligibility
ALL · 18 Years · 60 Years

Interventions & indications

Drugs
ASP4345

Sponsors

Astellas Pharma Global Development, Inc.Lead Sponsor

Investigators

1
Senior Medical DirectorStudy Director

Sites

1 total
Glendale, United States

Facts & assertions

4 sourced
Enrollment
48
Phase
PHASE1
Primary Completion Date
2017-06-08
Status
COMPLETED
relationships
The graph out of here
drug
ASP4345
drug
lead_sponsor
Astellas Pharma Global Development, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Senior Medical Director
person